Skip to main navigation

Careers
Investors & Media
Contact

SCIENCE
PIPELINE
DISEASE FOCUS
HAE COMMUNITY
CLINICAL TRIALS
ABOUT US

Events

Investor Menu

IR Nav

Overview
News & Events
News Releases Events Publications
Financials
SEC Filings Quarterly Results
Stock
Stock Performance Analyst Coverage
Corporate Governance
Governance Documents Leadership Board of Directors Committee Composition
Resources
Investor FAQs Contact Us Email Alerts

Upcoming Events

Jun 26, 2026 10:00 AM EDT

2026 Annual General Meeting of Shareholders

Add to Google Calendar

Supporting Materials

2025 Annual Report 4 MB

Convening Notice and Agenda 259.8 KB

Voting Proxy 198.5 KB

Past Events

Oct 3 - Oct 5, 2025

Joint XXXVII Italian Society of Allergology, Asthma, and Clinical Immunology (SIAAIC) National Congress and World Allergy Organization Congress (WAO)

Supporting Materials

Efficacy and Safety of Oral Deucrictibant for Prophylaxis and On-Demand Treatment of Attacks in Acquired Angioedema with C1 Inhibitor Deficiency: CREAATE Phase 3 Trial Design 185 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study 233.6 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 167.6 KB

Oct 2 - Oct 4, 2025

Deutscher Allergiekongress (DAK)

Supporting Materials

Durability of Response to a Single Dose of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks 1.4 MB

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 1.8 MB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study 1.5 MB

Oct 1 - Oct 4, 2025

Spanish Society of Allergology and Clinical Immunology (SEAIC)

Supporting Materials

Acquired Angioedema Due to C1-Inhibitor Deficiency: Conceptual Model of Patient Experience and Assessment of Patient-Reported Outcome Measures 334.3 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for the Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 1 MB

Durability of Response to a Single Dose of Oral Deucrictibant for the On-Demand Treatment of Hereditary Angioedema Attacks 979.3 KB

Sep 26 - Sep 28, 2025

Consortium of Independent Immunology Clinics (CIIC) Fall 2025 Conference

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study and Post-hoc Analysis on Durability of Response to a Single Dose of Oral Deucrictibant 345.5 KB

Long-Term Safety, Efficacy and Sustained Therapeutic Exposure of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension and Results of a Pharmacokinetics Study in Healthy Volunteers 1.3 MB

Sep 10, 2025 8:30 AM EDT

Morgan Stanley 23rd Annual Global Healthcare Conference

Click for Webcast

Sep 9, 2025 8:00 AM EDT

H.C. Wainwright 27th Annual Global Investment Conference

Click for Webcast

Sep 4, 2025 3:45 PM EDT

2025 Wells Fargo Healthcare Conference

Click for Webcast

Sep 3, 2025 11:30 AM EDT

Cantor Global Healthcare Conference 2025

Click for Webcast

Aug 27 - Aug 29, 2025

European Academy of Allergy & Clinical Immunology (EAACI) Hong Kong Allergy School 2025

Supporting Materials

Efficacy and Safety of Oral Deucrictibant for Prophylactic (CHAPTER-3) and for On-Demand (RAPIDe-3) Treatment of Hereditary Angioedema Attacks in Adolescents and Adults: Two Phase 3 Trial Designs 925.1 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylactic and On-Demand Treatment of Hereditary Angioedema Attacks: Results of the CHAPTER-1 and RAPIDe-2 Extension Trials 1.2 MB

Aug 7 - Aug 9, 2025

Argentine Association of Allergy and Clinical Immunology Congress

Supporting Materials

CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks  1.2 MB

RAPIDe-3 Phase 3 Trial Design: Oral Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks 1.6 MB

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Page 5
…
Next page
Last page

Presentations

Latest Corporate Presentation

FOLLOW US

©2026 Pharvaris N.V. © All Rights Reserved

Privacy Policy
Clinical Trial Privacy Notice
Global Privacy Laws
Terms of Use